Dr. Peter Martin Discusses RBAC500: A Combination of Cytarabine with Rituximab and Bendamustine for Elderly Patients with Mantle Cell Lymphoma

healio

In an interview recorded during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discussed  results from a phase 2 trial where researchers from the Fondazione Italiana Linfomi found that the addition of intermediate-dose of cytarabine to the first line treatment of rituximab and bendamustine led to a 91% response rate in elderly people with mantle cell lymphoma. This chemotherapy combination is known as RBAC500.

Dr. Peter Martin’s Manuscript Selected as Top 10 Manuscript for 2016

Earlier today the editors of Blood, the journal of the American Society of Hematology selected the top 10 most outstanding manuscripts of 2016. Dr. Peter Martin was the first author in one of the selected abstracts titled ‘Post Ibrutinib outcomes in patients with mantle cell lymphoma‘. (MCL)

Dr. Peter Martin
Dr. Peter Martin

Dr. Martin led a team of researchers at Weill Cornell Medicine and centers from around the world in a retrospective study of patients with MCL who experienced disease progression while receiving ibrutinib. These researchers found that MCL patients who progressed during treatment with ibrutinib have a poor outcome. As there are no therapies that appear to be uniquely successful in the post-ibrutinib setting this represents an unmet need.

You can read about the full results from their study in the abstract.

Congratulations Dr. Martin!

Dr. John Leonard Discusses Results from the GALLIUM Trial for Patients with Previously Untreated Follicular Lymphoma

jl

Click on the graphic above to watch this interview from the 2016 annual meeting of the American Society of Hematology, Lymphoma Program Director, Dr. John Leonard discusses results from the recently completed GALLIUM trial. In this trial researchers compared the safety and efficacy of either rituximab or obinutuzumab with chemotherapy followed by maintenance with the same agent as first-line therapy for patients with previously untreated follicular lymphoma.